KU Leuven and FIT Biotech Enter Into a Worldwide License Agreement
News Jul 30, 2013
KU Leuven and FIT Biotech have announced that they entered into a worldwide license and collaboration agreement for the development of novel immunotherapeutics based on FIT Biotech's proprietary Gene Transport Unit (GTU) technology for transient in vivo expression of monoclonal antibodies.
The agreement provides KU Leuven with an exclusive worldwide license to six undisclosed proprietary antibodies or marketed recombinant products.
“FIT Biotech continues to apply its platform technology in several therapeutic areas through collaborations and its own research and business development,” said Kalevi Reijonen, CEO and President, FIT Biotech Ltd.
Reijonen continued, “This agreement reflects our strategy to maximize the value of our technology by partnering with companies or universities that have a unique expertise to drive the development of promising vaccines or immunotherapeutics.”
“We are extremely delighted to collaborate with FIT Biotech and build further on their powerful technology platform,” said Nick Geukens, Research Manager of PharmAbs, the KU Leuven antibody center.
Geukens continued, “Our R&D program meets the clear need for more selective and effective management strategies to combat nosocomial infections and cancer. By commercializing our R&D programs we ultimately aim to establish a new, fully-dedicated Flemish spin-off company that will be responsible for (pre)clinical development and marketing of the generated products.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
Drug May Suppress Deadly Immune Response When Trauma Spills the Contents of Cell PowerhousesNews
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection. A drug that cleaves escaped proteins called N-formyl peptides appears to reduce resulting dangerous leakage from blood vessels and improve survival.READ MORE